MedTrace Logo

Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

NCT00536796 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1096

Last updated 2014-10-30

No results posted yet for this study

Summary

A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is \<100mg/dl for patients with high risk and \<70mg/dl for patients at very high risk) are screened (hospital-based specialists). The doctors therapy decisions after the screening and possible reasons for these decisions will be documented. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Josef Patsch, MD · Chair of the Austrian Atheroslerosis Society

  • Bernhard Foger, MD · Co-Chair of the Austrian Atheroslerosis Society

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00536796 on ClinicalTrials.gov